# Navigating Therapies, Challenges, and Recommendations for Treatment-Resistant Peripartum Depression: A Comprehensive Review

**Authors:** Afshan Zeeshan Wasti, Sarah Almutairi, Mohsina Huq, Amal Hussain, Amal Mohamad Husein Mackawy, Farah Jabeen, Basmah Alharbi, Anjuman Gul Memon, Mawahib Ahmed

PMC · DOI: 10.3390/healthcare13192426 · Healthcare · 2025-09-25

## TL;DR

This review explores effective and safe treatments for peripartum depression that doesn't respond to standard therapies, focusing on both drugs and non-drug options.

## Contribution

The paper provides a comprehensive review of treatment-resistant peripartum depression with a focus on balancing maternal and fetal safety.

## Key findings

- Pharmacological treatments like SSRIs and zuranolone show efficacy but raise fetal safety concerns.
- Non-pharmacological interventions such as CBT and rTMS offer safe and effective alternatives.
- Personalized treatment plans and expanded mental health infrastructure are recommended for better TRPD care.

## Abstract

Treatment-resistant peripartum depression (TRPD) is a significant public health concern due to the dual imperative of maternal symptom relief and fetal/neonatal safety with complex therapeutic challenges, particularly among expecting mothers worldwide. This comprehensive review focused on current pharmacological and non-pharmacological interventions for treatment-resistant depression (TRD)/peripartum depression (PPD), highlighting their mechanisms, efficacy, safety profiles, and practical considerations. The search strategy is based on PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis), using a systematic search of PubMed, Cochrane Library, and EMBASE for English-language articles published between 2000 and 2024, with a combination of Medical Subject Headings (MeSH) and free-text terms for TRD/TRPD. After screening, the initial search yielded 142 articles; only 67 articles were qualified for eligibility and quality assessment. According to related research, pharmacological treatments such as SSRIs or brexanolone and zuranolone can be effective in addressing TRPD challenges, but they carry concerns regarding fetal and neonatal risk. In contrast, non-pharmacological interventions—such as cognitive behavioral therapy (CBT), repetitive transcranial magnetic stimulation (rTMS), and exercise—offer safe, evidence-based alternatives that are becoming increasingly accessible. Our findings imply that innovative therapeutics and integration of these interventions personalized to individual needs are the optimal clinical approach that may help in balancing maternal symptom control and perinatal safety. Also, expanded mental health infrastructure with enhanced research is essential for advancing TRPD care.

## Linked entities

- **Chemicals:** brexanolone (PubChem CID 92786), zuranolone (PubChem CID 86294073)

## Full-text entities

- **Diseases:** PPD (MESH:D003866), TRD (MESH:D061218)
- **Chemicals:** zuranolone (MESH:C000634505), brexanolone (MESH:C000625635)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12523947/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12523947/full.md

## References

69 references — full list in the complete paper: https://tomesphere.com/paper/PMC12523947/full.md

---
Source: https://tomesphere.com/paper/PMC12523947